SEC Form 4 · accession 0001720081-17-000007
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luis Diaz
Director
Period of report
Oct 20, 2017
Accepted (ET)
Oct 23, 2017 · 8:29 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $14.78 | Oct 20, 2017 | A | 27,100 | A | — | Oct 20, 2027 | Common Stock | 27,100 | 27,100 | D |
Explanation of responses
- F1This option was granted on October 20, 2017 and will vest in equal quarterly installments during the twelve quarters following the grant date.